Mizacorat - AstraZeneca
Alternative Names: AZD 9567; AZD9567-monohydrateLatest Information Update: 05 Nov 2023
At a glance
- Originator AstraZeneca
- Class Amides; Antirheumatics; Benzene derivatives; Ethers; Fluorinated hydrocarbons; Indazoles; Pyridines; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
- No development reported Respiratory tract disorders
Most Recent Events
- 14 Aug 2023 Chemical structure information added
- 29 Jun 2021 AstraZeneca completes the phase II trial in Rheumatoid arthritis in Germany (PO) in June 2021 (EudraCT2020-000931-35) (NCT04556760)
- 02 Jun 2021 Efficacy and adverse events data from a phase II clinical trial in Rheumatoid arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism (EULAR-2021)